Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity. The trailing-twelve-month return on equity at Akorn (NASDAQ: AKRX ) is 20.78%. Akorn's revenue for the same period is $304.28 million. The trailing-twelve-month return on equity at Salix Pharmaceuticals (NASDAQ: SLXP ) is 17.90%. Salix